Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPANGIO neoadjuvant propranolol monotherapy in angiosarcoma
2019-002947-41Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in angiosarcoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical response. Started Oct 2019; status: completed.
02
Drugs
propranolol
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on 2019-002947-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002947-41.